Assetmark Inc. has made headlines after disclosing that the institutional investor boosted its stake in Arrowhead Pharmaceuticals, Inc. by 6.5% during the fourth quarter of the year 2022. The recent disclosure was made by Assetmark Inc. to the Securities and Exchange Commission (SEC) and revealed that it now owns a total of 83,965 shares in the biopharmaceutical company, worth $3,406,000. This translates to approximately 0.08% ownership of Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had released strong earnings results on May 2nd this year – reporting earnings per share of $0.45 for Q1 and beating analyst estimates that were pegged at ($0.65) by a significant margin of $1.10 per share. The company’s net margin was negative at 53.83% while its return on equity stood at -33.49%. During the same period last year, Arrowhead Pharmaceuticals reported earnings per share (EPS) of $0.41; therefore, the business saw some growth as EPS rose between years; however, revenue did decline YoY from $151.63 million to $146.27 million.
Arrowhead is engaged in developing medicines designed to treat intractable diseases caused by silencing genes responsible for those diseases shortly after diagnosis through RNAi therapy technology like ARO-APOC3 and ARO-ANG3 among others mentioned above which are still in their preclinical stage.Their ultimate target is often Nucleic Acid Therapeutics designed for various clinical indications where targets are liver-based causing hepatic disease.Its innovative approach has put it ahead of many competitors looking into a similar field.
Sell-side analysts have an average estimate that Arrowhead Pharmaceuticals will post -1.38 EPS for this fiscal year, based on historical data and trends from previous years as well as current industry trends.A number of institutional investors around the world have bought into Arrowhead Pharmaceuticals, and we can expect more news from other parties showing interest. Many institutional buyers seem to believe that biotech stocks will see substantial growth over the next few years due to the rise of gene therapies and new tech in this area.This puts companies like Arrowhead Pharmaceuticals at a prime position for major advancements in these fields, making it an exciting prospect for investors wanting innovation and diversification.
[bs_slider_forecast=”ARWR”]
Investment in Arrowhead Pharmaceuticals: Market Outlook and Recent Activity
Arrowhead Pharmaceuticals: Understanding the Recent Investment Activity and Market Outlook
The recent rise in investment activity by large institutional investors in Arrowhead Pharmaceuticals has caught the attention of both industry analysts and investors. On May 28, 2023, US Bancorp DE grew its stake in Arrowhead Pharmaceuticals by 6.5% in the first quarter, followed by HighTower Advisors LLC and Rhumbline Advisers with a 4.9% and 2.4% increase respectively. Commonwealth of Pennsylvania Public School Empls Retrmt SYS also increased its stake by 11.8% during the same period.
BlackRock Inc is now one of the major shareholders with a position in Arrowhead Pharmaceuticals, owning 12,155,084 shares worth $559,014,000 – or approximately 65.46% – of the company’s overall value.
According to providing biopharmaceutical company Arrowhead Pharmaceuticals (NASDAQ: ARWR), it has been engaged actively in developing medicines for treating intractable diseases using gene silencing technology. The preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV and ARO-ENaC.
Despite news that Director Douglas B. Given had sold over 73k shares valued at $2.81m within a ninhety-day period CEO Christopher Anzalone remains hopeful about future prospects stating “Our pipeline is progressing well without significant disruption from ongoing sampling fatigue…financially we are stable with strong cash reserves…we remain optimistic for our future growth.”
Despite such optimism coming from within the organisation several research firms have issued reports on ARWR predicting less than optimistic outlooks for their future growth potential as an investment opportunity going forward.
Canadian financial services unicorn Royal Bank of Canada reduced its price target on Arrowhead Pharmaceuticals from $83.00 to $77.00 and issued an “outperform” rating for the company in a research note published on February 7th, 2023. Robert W. Baird dropped its price target on shares of Arrowhead Pharmaceuticals from $60.00 to $58.00 and set an equally optimistic “outperform” rating on the stock in a research report released in early February.
Earlier this year Sumitomo Mitsui Financial Group had issued coverage of the company as stock; evaluating it with an “outperform” rating issuing a positive target price upon their shares of $80.00. While Piper Sandler reported less optimal long-term standings of the share stating concerns as such in delivering any future earnings growth.
Following all latest developments regarding Arrowhead Pharmaceuticals, Bloomberg reports current activity pointing towards suggesting a total investment return for ARWR shareholder portfolio holders labeled as “Moderate Buy”, with long-term predictions remaining to be seen at present.
